Smoldering Inflammation in MS

Part of paid clinical trials in St Louis, Missouri.

Sponsor
Washington University School of Medicine
Study ID
NCT06591429
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Radiotracer [11C]-CS1P1 — RADIATION
    Radiotracer used in PET/CT scans of the head and neck Dose range: 12-17 mCi
  • Radiotracer [11C]-DPA-713 — RADIATION
    Radiotracer used in PET/CT scans of the head and neck Dose range:15-20 mCi
  • anti-CD20 MS treatment — DRUG
    MS treatment taken indepenently after initial testing
  • Radiotracer [12F]-FDG — RADIATION
    used in PET/CT scans of the head and neck Dose: 5-7 mCi

Study Details

The goal of this observational study is to learn about inflammation in those with relapsing remitting Multiple Sclerosis (MS). The main questions it aims to answer are: * How does abnormal neural inflammation compare to cellular and molecular inflammation in MS? * Once treated, why does abnormal inflammation persist?

Key Dates

Start date
Jun 19, 2024
Status verified
Dec 2025
Primary completion
Jun 30, 2027
Completion
Jun 30, 2027

Study Design

Enrollment
25 participants (estimated)

Arms

  • Arm: Participants
    Adults with MS taking part in this study.

Primary Outcome Measure

Volume of Distribution (Vt) of DPA-713 and CS1P1 and Cerebral metabolic rate of glucose (CMRglc) in white matter lesions and normal appearing white matter before and after treatment. [ Time Frame: 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Barnes Jewish Center for Clinical Imaging ResearchSt LouisMissouri63110
Matthew R Brier, MD, PhD
314-362-7666
Nicole E Shelley, MA
Matthew R Brier, MD, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in St Louis, MO

By condition

Related Studies